Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Developme... (ldcause our actual results performance o...)

Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program

Date:7/9/2008

ld cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements, including, among others: our ability to obtain the capital required for research and operations, the inherent risks in early stage drug development including demonstrating efficacy, development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our Annual Information Form underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Lorus Therapeutics Inc.'s recent press releases are available through the Company's website at http://www.lorusthera.com. For Lorus' regulatory filings on SEDAR, pl
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway

Post Your Comments:

(Date:12/16/2009)... Corporation (Nasdaq: MATK ) today announced its financial ... October 31, 2009. Revenues for the fourth quarter were ... fourth quarter of fiscal 2008. Net income was $11.0 ... quarter of fiscal 2009, a 5% increase compared with ... year,s fourth quarter. The fourth quarter of fiscal ...

(Date:12/16/2009)... in suspended solution by swimming , ... ... at the U.S. Department of Energy’s (DOE) Argonne National Laboratory ... can turn microgears when suspended in a solution, providing insights ... , ,“The gears are a million times more massive than ...

(Date:12/16/2009)... Decision Resources, one of the world,s ... healthcare issues, finds that, according to responses from ... briakinumab (both interleukin inhibitors) will capture 22 percent ... drug market for moderate to severe psoriasis. Among ... capturing nearly three times as much patient share ...

(Date:12/16/2009)... conducted pursuant to Special Protocol Assessment with ... CITY, Dec. 16 /PRNewswire-FirstCall/ - AEterna Zentaris ... (the "Company"), a global biopharmaceutical company focused ... the initiation, by its partner Keryx Biopharmaceuticals ... 3 registration clinical trial for perifosine (KRX-0401), ...

[0] Martek Announces Fourth Quarter and FY 2009 Financial Results [0] Argonne Scientists Use Bacteria to Power Simple Machines [0] In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market [0] AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma

... policy areas that the new administration must address will ... technology that has been compared with the industrial revolution ... right decisions are made, nanotechnology will bring vast improvements ... wrong decisions are made, the American economy, human health ...

... MADISON, N.J., July 9 Wyeth (NYSE: WYE ... of law on the,punitive damages award in the hormone therapy ... Eastern District of Arkansas, has been,granted by the court. This ... Little Rock jury last year. The decision also,clears the way ...

... First sales for revolutionary CTO Crossing System after ... Israeli medical device company, has announced today the ... product-line for angiographic procedures in the peripheral vasculature. ... the treatment of chronic complete arterial blockage (CTO). ...

Other Biology Technology:Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 2 Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 3 Ovalum Ltd. Announces Sales Launch of CiTop™ Product-Line in Europe 2

Nanotechnology oversight: An agenda for the new administration Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court Ovalum Ltd. Announces Sales Launch of CiTop™ Product-Line in Europe

(Date:12/16/2009)... Medicine researcher will lead the coordinating center for a ... field of stem cell research. Michael L. Terrin, M.D.,C.M.,M.P.H., ... the National Heart, Lung and Blood Institute (NHLBI) to ... which will be called the NHLBI Progenitor Cell Biology ... $30 million grant over seven years. , ...

(Date:12/16/2009)... 1 GestureTek Inc. today announced ... - a turnkey, portable, plug and play ... entertainment and touring promotions. GestureTek is the ... in camera-enabled gesture recognition technology for interactive ... for quality, the CUBE has TUV, CE, ...

(Date:12/16/2009)... REDWOOD SHORES, Calif. and PALM HARBOR, Fla., ... ("CIC") (OTC Bulletin Board: CICI), a leading ... process automation in the financial industry* and ... and Docubase Systems Inc. ("Docubase"), a leading ... announced today that they have entered an ...

[0] University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium [0] GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits [0] CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions

... scientists are joining forces to conceptualize, develop and bring ... century health care through UC San Diego,s new Institute ... molecular-sized bridges to repair damaged hearts, and scarless surgery ... in California with the new Institute leading the way. ...

... an instrument designed to help determine the shapes and ... in high-altitude clouds, down to the micron level (comparable ... to a new study in Optics Letters, ... produced using this instrument likely will help improve computer ...

... children with autism evaluate facial expressions differently than the ... is strikingly similar to autistic patients themselves, according to ... University of North Carolina at Chapel Hill and neuroscientist ... , Piven, Adolphs and colleague Michael Spezio, Ph.D., ...

Other Biology News:UC San Diego launches Institute of Engineering in Medicine to accelerate health care tech 2 UC San Diego launches Institute of Engineering in Medicine to accelerate health care tech 3 Scientists demonstrate the sharpest measurement of ice crystals in clouds 2 UNC, Caltech research finds further evidence for genetic contribution to autism 2 UNC, Caltech research finds further evidence for genetic contribution to autism 3

UC San Diego launches Institute of Engineering in Medicine to accelerate health care tech Scientists demonstrate the sharpest measurement of ice crystals in clouds UNC, Caltech research finds further evidence for genetic contribution to autism

GOAT ANTI HUMAN PARAINFLUENZA VIRUS 2+3...

... The Varian Cary 50 Microplate ... your cost per analysis by ... of the award-winning Cary 50 ... up to 384 samples in ...

IMAGEQUANT 300 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....

PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...

Biology Products:

Goat Anti-Human PARAINFLUENZA VIRUS 2+3 Polyclonal Antibody, Unconjugated from AbD Serotec Cary 50 Microplate Reader Accessory from Varian, Inc.IMAGEQUANT 300 WKSTN from GE Healthcare, formerly Amersham Biosciences Rabbit Anti-Human IFN-Alpha / Beta R2 (IFNAR2) (CD118) Neutralizing Polyclonal Antibody, Unconjugated from PBL InterferonSource

Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Developme...(ldcause our actual results performance o...)